Nevin Manimala

Clin Oral Investig. 2022 Aug 27. doi: 10.1007/s00784-022-04680-x. Online ahead of print.

ABSTRACT

OBJECTIVES: The purpose of this randomized clinical trial (RCT) is to compare xenogeneic collagen matrix (XCM) versus subepithelial connective tissue graft (SCTG) to increase soft tissue thickness at implant site.

MATERIALS AND METHODS: The study was a randomized, parallel-group controlled investigation. Thirty patients underwent buccal soft tissue thickness augmentation at the stage of implant placement by two different methods: SCTG (control group) and XCM (test group). Primary outcome was the amount of buccal soft tissue thickness gain, 3 months after the intervention. Secondary outcomes were the operation time, the amount of keratinized mucosa (KM), pain syndrome (PS), and patients’ quality of life (QL). Histologic evaluation was also performed.

RESULTS: The amount of soft tissue thickness gain was 1.55±0.11 mm in SCTG group, and 1.18±0.11mm in XCM group. The difference between the SCTG and XCM was -0.366 (-0.66 to -0.07; p=0.016). Operation time with XCM was 8.4 (3.737 to 13.06) min shorter than that with the SCTG (p=0.001). KT, PS, and QL for both groups were not statistically significantly different at any time point (p>0.05). At histological examination, the general picture in both groups was similar. No significant differences between the studied groups in most indices, except for the average and maximum formation thickness, cellularity of the basal, mitotic activity and also maximum length of rete ridges.

CONCLUSION: Within limitations, this study demonstrates that the use of SCTG provides a statistically significant superior soft tissue thickness gain than XCM for soft tissue augmentation procedures around implants.

CLINICAL RELEVANCE: XCM can be used as the method of choice for increasing the thickness of soft tissues.

PMID:36029335 | DOI:10.1007/s00784-022-04680-x

Int J Fertil Steril. 2022 Aug 21;16(3):247-251. doi: 10.22074/ijfs.2022.540950.1205.

ABSTRACT

Recurrent pregnancy loss (RPL) complication is a challenge of reproductive medicine due to its often unknown etiology.<br />A case-control study was carried out between June 2019 and April 2020 to examine the correlation between RPL<br />and inherited thrombophilia (IT), namely mutations in factor V Leiden (FVL G1691A), prothrombin (FII G20210A),<br />and methylenetetrahydrofolate reductase (MTHFR C677T). A total of 120 Lebanese women with RPL was studied<br />and compared, for the frequency of these mutations, to 100 healthy reproductive Lebanese women. The association<br />between the zygosity status of the three tested mutations, the existence of more than one prothrombotic single nucleotide<br />polymorphisms (SNPs), and the increased risk of RPL were examined using Chi-square or two-tailed fisher exact<br />test, and the student t test. The predictive factors of RPL were analyzed using a multiple logistic regression model.<br />P<0.05 was considered to be statistically significant. Our results showed statistically significant higher frequencies<br />of FVL G1691A and FII G20210A mutations among the cases with RPL compared to the control group. Thus, RPL is<br />associated with FVL G1691A and FII G20210A mutations. These mutations seem to increase the risk of RPL in the<br />Lebanese women. Therefore, we suggest thrombophilia screening and adequate genetic counseling for women with<br />RPL and at high-risk to plan for primary prevention, avoiding thromboembolic or obstetric accidents, and reducing<br />the associated morbidity and mortality among Lebanese women.

PMID:36029065 | DOI:10.22074/ijfs.2022.540950.1205

Int J Fertil Steril. 2022 Aug 21;16(3):237-243. doi: 10.22074/ijfs.2022.544706.1236.

ABSTRACT

Present study assessed whether Sinopharm, AstraZeneca, Sputnik V, and Covaxin’s vaccinated women<br />reveal a distinct incidence of menstruation disturbances, hirsutism, and metrorrhagia.<br />Materials and Methods: Data collection was performed from June to August 2021, and 427 women working in seven<br />selected hospitals in Tehran were studied in this descriptive-analytical cross-sectional study. All of these women had<br />received one or both doses of the vaccines with one of the assessed vaccines. Required data was collected via questionnaire<br />and imported to SPSS 16 for further assessment and analysis. Fisher’s Exact Test and Chi-Squared test were<br />main statistical tests used to understand whether any significant relation exists or not.<br />Results: The participant’s mean age and body mass index (BMI) were 29.78 ± 10.55 and 23.27 ± 3.82, respectively.<br />Three hundred ninety-five cases (92.4%) had received both doses of the vaccines. Also, 154 cases (36.1%) had a history<br />of COVID-19. A total of 38 cases (8.8%) of menstruation disturbances, 20 cases (4.6%) of metrorrhagia, and 7<br />cases (1.6%) of hirsutism were reported after receiving the vaccines. There was a significant difference among the<br />vaccinated groups with the vaccines as mentioned earlier in terms of menstruation disturbances (hypermenorrhea,<br />dysmenorrhea, Amenorrhea) (P=0.01). The highest and the lowest incidence of menstruation disturbances were recorded<br />in the group vaccinated with Covaxin (17.6%) and Sputnik V (5%), respectively. There was also no significant<br />difference amongst the vaccinated groups with the four vaccines regarding the incidence of metrorrhagia and<br />hirsutism (P=0.10 and P=0.12, respectively). There was no significant relationship between all three complications<br />incidence with the previous infection concerning all vaccines (coefficient=0.46, 1.27, -0.15 respectively for menstruation<br />disturbances, metrorrhagia, and, hirsutism).<br />Conclusion: Seemingly, Covaxin revealed the most side effects in terms of menstruation disturbances. As a result, professionals<br />must carry out several studies with reasonable samples to recommend the vaccine to those women confidently.

PMID:36029063 | DOI:10.22074/ijfs.2022.544706.1236

Int J Fertil Steril. 2022 Aug 21;16(3):211-219. doi: 10.22074/ijfs.2021.529258.1124.

ABSTRACT

Recurrent pregnancy loss (RPL) and infertility are associated with significant psychiatric complications.<br />The study aimed to investigate the effectiveness of cognitive behavioral therapy (CBT) and sertraline<br />in the treatment of in depression, anxiety, and infertility stress of depressed infertile women with RPL in comparison<br />with usual care.<br />Materials and Methods: A triple-arm randomized controlled trial was carried out on the 60 depressed infertile<br />women with RPL, a population of Infertility Center of Babol city, Iran, who were randomly assigned into three<br />groups: pharmacotherapy with sertraline (n=20), psychotherapy with CBT (n=20), and a usual care as control<br />group (n=20). The participants of psychotherapy received CBT sessions (90 minutes each) over 10 weeks. The<br />participants in the pharmacotherapy group took 50 mg/day sertraline daily for 22 weeks. Outcomes were assessed<br />using the Beck Depression Inventory (BDI-II), fertility problem inventory (FPI), and State-Trait Anxiety<br />Inventory Form Y (STAI-Y) at the beginning of the trial, 10-weeks post-trial, and three months of follow-up.<br />Using statistical package for the social sciences (SPSS) software, data were analyzed.<br />Results: CBT considerably reduced the depression symptoms more than sertraline with a moderate effect size<br />at the post-trial (g=0.11, 95% CI: -0.03 to -0.50). Sertraline showed reduced the scores of state-anxiety more<br />considerably in comparison with control group by a large effect size of post-trial (g=-1.04, 95% CI: -1.70 to<br />-0.38). CBT reduced the total scores of FPI more considerably than sertraline, with a large, small size at follow<br />up-trial [95% CI=-0.03(-0.65, -0.58)]. Both CBT and sertraline were superior to the control group in reducing<br />depression and infertility stress.<br />Conclusion: Depression and infertility stress diminished under CBT and sertraline in depressed infertile women with<br />RPL, with a significant advantage of CBT. Sertraline was superior to CBT in reduction of anxiety (registration number:<br />IRCT201304045931N3).

PMID:36029059 | DOI:10.22074/ijfs.2021.529258.1124

Int J Fertil Steril. 2022 Aug 21;16(3):206-210. doi: 10.22074/ijfs.2021.521378.1066.

ABSTRACT

The purpose of this prospective study was to compare the ovarian response and pregnancy outcomes<br />in the infertile women with endometrioma undergoing assisted reproductive technologies (ART) in two<br />groups, who were underwent laparoscopic cystectomy and received gonadotropin releasing hormone-agonist<br />(GnRH-agonist) and who only received GnRH-agonist without any surgery.<br />Materials and Methods: In this prospective clinical trial study, 79 infertile women with asymptomatic endometriomas<br />cyst (2-6 cm) were enrolled and randomly assigned to two groups. First group underwent laparoscopic<br />cystectomy and received GnRH-agonist. Second group only received GnRH-agonist without any surgery. Following<br />ovulation induction, all patients underwent intracytoplasmic sperm injection (ICSI). Different parameters<br />such as the number of retrieved oocytes and embryos; were made our outcomes that analyzed using SPSS.<br />Results: The pregnancy rate, chemical and clinical, and live birth rate were higher in the combined group,<br />although these differences were not statistically significant (48.48% vs. 30.8%, P=0.12, 36.36% vs. 25.6%,<br />P=0.32, 36.36% vs. 23.1%, P=0.29). The number of injections, antral follicles, retrieved oocytes, mature oocytes,<br />total embryos, transferred embryos and duration of stimulation were similar in two groups.<br />Conclusion: Laparoscopic cystectomy followed by receiving GnRH-agonist improves pregnancy outcomes in endometrioma<br />prior to treatment with ART (registration number: IRCT201106116689N2).

PMID:36029058 | DOI:10.22074/ijfs.2021.521378.1066

Int J Fertil Steril. 2022 Aug 21;16(3):180-183. doi: 10.22074/ijfs.2021.141690.1050.

ABSTRACT

BACKGROUND: Polycystic ovary syndrome (PCOS) is known as the most common endocrine and metabolic disorder in the reproductive-age women. Due to the effects of PCOS on the physical and mental health, the investigation of the factors affecting the development of PCOS is crucial. Hexose-6-phosphate dehydrogenase (H6PD) is a microsomal enzyme that catalyzes the first two reactions of the oxidative chain of the pentose phosphate pathway. The present study examined the polymorphisms of the H6PD gene (R453Q and D151A) in PCOS patients of Iranian Kurdish women.<br />Materials and Methods: In this case-control study, a total, of 200 female volunteers in two equal groups participated in our study. The PCOS patients were selected based on the Rotterdam diagnostic criteria. The association of H6PD gene polymorphisms, D151A and R453Q, with the development of PCOS were investigated. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping. Statistical analysis was applied by the SPSS (version 16) software.<br />Results: Statistically significant lower frequencies of AA+AG genotype (37% vs. 55%, P=0.01) and A allele (22.5%<br />vs. 34%, P=0.01) of R453Q were observed in the patients compared to the controls. In the case of D151A, no significant<br />differences were observed in the frequency of genotypes and alleles between the two groups.

CONCLUSION: The findings of this study suggest that variants of H6PD R453Q affect the risk of PCOS.

PMID:36029054 | DOI:10.22074/ijfs.2021.141690.1050

Int J Fertil Steril. 2022 Aug 21;16(3):162-166. doi: 10.22074/ijfs.2021.532311.1141.

ABSTRACT

Few studies have so far been done about the role of follicle stimulating hormone (FSH) in final oocyte<br />maturation. However, none of these studies have been performed solely on normoresponder patients. This study aimed<br />to determine whether oocyte maturation, as well as fertilization and pregnancy rates, could be improved in normoresponder women with concomitant FSH and human chorionic gonadotropin (hCG) trigger compared to those with the hCG trigger alone.<br />Materials and Methods: In this prospective randomized clinical trial, 117 normoresponder women, aged 19-40 years<br />who were candidates for the gonadotropin-releasing hormone (GnRH) antagonist protocol at Avicenna Infertility<br />treatment Center, were enrolled and claasified in two groups. Final oocyte maturation was triggered using 10000 IU of<br />hCG plus 450 IU of FSH in the first group (59 subjects) and 10000 IU of hCG alone in the second group (58 subjects).<br />The primary outcome was clinical pregnancy rate.<br />Results: Mean age of the patients was 33.21 ± 4.41 years. There was no difference in clinical pregnancy among the<br />two groups (30.9% vs. 25.5%, P=0.525). There was no statistically significant difference in fertilization rate (80.0%<br />vs. 74.1%, P=0.106), implantation rates (18.9% vs. 16.7%, P=0.352), and chemical pregnancy rates (38.2% vs. 32.7%,<br />P=0.550). Oocyte maturation rate (84.2% vs. 73.6%, P<0.001), 2 pronuclei (2PNs) (6.53 ± 2.54 vs. 5.36 ± 2.85,<br />P=0.021) and total embryos (5.85 ± 2.43 vs. 4.91 ± 2.58, P=0.046) were significantly higher in the first group.<br />Conclusion: Adding FSH to hCG for oocyte triggering, significantly improved oocyte maturation rates and total embryos.<br />While there was no significant difference in the clinical and chemical pregnancy rates, between these two groups<br />(registration number: IRCT20190108042285N1).

PMID:36029051 | DOI:10.22074/ijfs.2021.532311.1141

Int J Fertil Steril. 2022 Aug 21;16(3):156-161. doi: 10.22074/ijfs.2021.532258.1140.

ABSTRACT

Accurate etiology of azoospermia is required for optimal management of patients. The aim of this<br />study was the determination of serum hormonal levels and testicular long axis cut off points to distinguish obstructive<br />azoospermia (OA) from non-OA (NOA) in Iranian patients as well as the evaluation of the necessity of diagnostic<br />testis biopsy in azoospermic patients.<br />Materials and Methods: In this retrospective study, data of 471 azoospermic patients such as history and physical<br />examination, serum hormonal level, semen fluid parameter, and testicular long axis based on ultrasound were<br />evaluated from 2016 to 2020. All patients were examined by a single urologist and underwent a diagnostic testis<br />biopsy for a definite diagnosis. The diagnostic parameters were analyzed using Statistical Package for the Social<br />Sciences (SPSS) version 16 with t test and chi-square test and receiver operating characteristic (ROC) curves to<br />distinguish NOA from OA.<br />Results: A total of 127 patients with OA and 284 with NOA were included in this study. The mean serum testosterone<br />level was significantly higher in OA than NOA (4.2 vs. 3.4 ng/ml), whereas the mean serum follicular stimulating hormone<br />(FSH, 5.3 vs. 19.1 mIU/ml) and luteinizing hormone (LH, 5.3 vs. 11 mIU/ml) were lower in OA. ROC curve analysis<br />showed that FSH and testicular long axis were the best diagnostic predictors. Using a combination of serum FSH (8.9<br />mIU/ml) and testicular long axis (39 mm), the positive predictive value for NOA was 97.02% and for OA was 78.8%.<br />Conclusion: Combination of serum FSH higher than 8.9 mIU/ml and testicular long axis lower than 39 mm were<br />strong predictors to distinguish NOA from OA in Iranian participants in this study. In addition, diagnostic testicular<br />biopsy seems to be necessary for patients with OA and NOA characteristics.

PMID:36029050 | DOI:10.22074/ijfs.2021.532258.1140

Acta Neurol Scand. 2022 Aug 27. doi: 10.1111/ane.13676. Online ahead of print.

ABSTRACT

Vestibular neuritis is a common neuro-otological entity. Therapeutically, corticosteroids are advised, although the evidence is limited. The objective of this review is to update meta-analyses of clinical trials that address the question of whether patients with vestibular neuritis treated with corticosteroids show better recovery than control patients. The electronic databases Medline, Scopus and Cochrane were searched for clinical trials for the years 1970-2020 without language restriction. Data were extracted, and outcome parameters were subjected to conventional and cumulative meta-analysis using a commercially available software program (www.meta-analysis.com). Finally, 15 trials with 363 participants in the treatment and 489 in the control groups were identified and could be included. Eight studies were judged to be at high risk of bias. The odds ratio (OR) for good outcome in the acute phase was 3.1 (95% CI 1.2-7.8; p = .015) in favour of steroid treatment leading to the number needed to treat (NNT) = 6 (95% CI 4-23). The odds ratio (OR) for restoration of vestibular function in the follow-up was 2.4 (95% CI 1.3-4.4; p = .004) for the benefit of steroid treatment resulting in a NNT = 7 (95% CI 5-18). The results of the cumulative statistics did not differ. The risk of adverse effects was higher in patients treated with steroids with an OR of 10.9 (95% CI 1.3-93.8; p = .015) and an estimated number needed to harm (NNH) = 4 (95% CI 3-19). The advantage for corticosteroids remained when differentiating between patients who participated in randomized or non-randomized clinical trials. Steroid treatment in vestibular neuritis resulted in a statistically significant benefit compared to control therapies. However, broad heterogeneity of the studies, mostly low-grade quality of studies, high risk of bias and broad confidence intervals put the findings into perspective allowing only a careful judgement of some benefit of corticosteroids. The findings, however, support the call for an adequately powered and well-designed randomized controlled trial to re-evaluate the effectiveness of corticosteroids.

PMID:36029039 | DOI:10.1111/ane.13676

Chem Biol Drug Des. 2022 Aug 4. doi: 10.1111/cbdd.14125. Online ahead of print.

ABSTRACT

Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver and key therapeutic target for human cancers. Current therapies targeting HER2 are primarily based on overexpression of the wild-type form of HER2. However, kinase domain mutations have been identified that can increase the activity of HER2 even when expressed at basal levels. Using purified enzymes, we confirmed the hyperactivity of two HER2 mutants (D769Y and P780insGSP). To identify small molecule inhibitors against these cancer-associated variants, we used a combined approach consisting of biochemical testing, similarity-based searching, and in silico modeling. These approaches resulted in the identification of a candidate molecule that inhibits mutant forms of HER2 in vitro and in cell-based assays. Our structural model predicts that the compound takes advantage of water-mediated interactions in the HER2 kinase binding pocket.

PMID:36029027 | DOI:10.1111/cbdd.14125